PROTEON THERAPEUTICS, INC. (NASDAQ:PRTO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders |
|
(a)The Companysannual meeting of stockholders was held on June 20, 2017. |
|
|
(b)The stockholders elected all of the Companys nominees for directors and ratified the appointment of Ernst and Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2017.The tabulation of votes for each proposal is as follows: |
|
| Proposal 1 – Election of Directors |
| For | Withheld | Broker Non-Votes | ||
| Scott A. Canute | 11,017,667 | 226,380 | 4,124,217 | |
| Tim Haines | 11,019,212 | 224,835 | 4,124,217 |
|
Proposal 2 – Ratification of Independent Registered Public Accounting Firm |
| For | Against | Abstentions | ||
| 15,329,819 | 15,079 | 23,366 |
About PROTEON THERAPEUTICS, INC. (NASDAQ:PRTO)
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
